TY - JOUR
T1 - Cystic fibrosis pulmonary guidelines
T2 - Treatment of pulmonary exacerbations
AU - Flume, Patrick A.
AU - Mogayzel, Peter J.
AU - Robinson, Karen A.
AU - Goss, Christopher H.
AU - Rosenblatt, Randall L.
AU - Kuhn, Robert J.
AU - Marshall, Bruce C.
AU - Bujan, Janet
AU - Downs, Anne
AU - Finder, Jonathan
AU - Goss, Chris
AU - Gutierrez, Hector
AU - Hazle, Leslie
AU - Lester, Mary
AU - Quittell, Lynne
AU - Sabadosa, Kathryn
AU - Vender, Robert L.
AU - White, Terry B.
AU - Willey-Courand, Donna Beth
AU - Saldanha, Ian
AU - Oyegunle, Modupe
AU - Shankar, Manjunath B.
AU - Mckoy, Naomi
AU - Sengupta, Shaon
AU - Odelola, Olaide Adebomi
AU - Waybright, Sarah
PY - 2009/11/1
Y1 - 2009/11/1
N2 - The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations These exacerbations typically warrant medical intervention. It is important that appropriate therapies are recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to define the key questions related to pulmonary exacerbations, review the clinical evidence using an evidence-based methodology, and provide recommendations to clinicians. It is hoped that these guidelines will be helpful to clinicians in the treatment of individuals with cystic fibrosis.
AB - The natural history of cystic fibrosis lung disease is one of chronic progression with intermittent episodes of acute worsening of symptoms frequently called acute pulmonary exacerbations These exacerbations typically warrant medical intervention. It is important that appropriate therapies are recommended on the basis of available evidence of efficacy and safety. The Cystic Fibrosis Foundation therefore established a committee to define the key questions related to pulmonary exacerbations, review the clinical evidence using an evidence-based methodology, and provide recommendations to clinicians. It is hoped that these guidelines will be helpful to clinicians in the treatment of individuals with cystic fibrosis.
KW - Aminoglycosides
KW - Drug synergism
KW - IV antibiotics
KW - Pseudomonas
KW - Respiratory therapy
UR - http://www.scopus.com/inward/record.url?scp=70350446684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350446684&partnerID=8YFLogxK
U2 - 10.1164/rccm.200812-1845PP
DO - 10.1164/rccm.200812-1845PP
M3 - Review article
C2 - 19729669
AN - SCOPUS:70350446684
SN - 1073-449X
VL - 180
SP - 802
EP - 808
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
IS - 9
ER -